ERBB2 and breast carcinoma: Afatinib (BIBW 2992) is another irreversible, oral pan-HER inhibitor, which has demonstrated activity in early-phase trials of advanced solid tumors and trastuzumab-refractory HER2-positive breast cancer [22].